Novavax Management
Management criteria checks 1/4
Novavax's CEO is John Jacobs, appointed in Jan 2023, has a tenure of 1.83 years. total yearly compensation is $7.30M, comprised of 9.1% salary and 90.9% bonuses, including company stock and options. directly owns 0.03% of the company’s shares, worth €386.57K. The average tenure of the management team and the board of directors is 1.8 years and 4.3 years respectively.
Key information
John Jacobs
Chief executive officer
US$7.3m
Total compensation
| CEO salary percentage | 9.1% |
| CEO tenure | 1.8yrs |
| CEO ownership | 0.03% |
| Management average tenure | 1.8yrs |
| Board average tenure | 4.3yrs |
Recent management updates
No updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$285m |
| Jun 30 2024 | n/a | n/a | -US$294m |
| Mar 31 2024 | n/a | n/a | -US$399m |
| Dec 31 2023 | US$7m | US$663k | -US$545m |
Compensation vs Market: John's total compensation ($USD7.30M) is above average for companies of similar size in the Austrian market ($USD1.89M).
Compensation vs Earnings: Insufficient data to compare John's compensation with company performance.
CEO
John Jacobs (57 yo)
1.8yrs
Tenure
US$7,301,009
Compensation
Mr. John Charles Jacobs, M.B.A., serves as Chief Executive Officer and Director of Novavax, Inc. since January 23, 2023 and serves as its President from January 23, 2023. He was Director of Life Sciences P...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 1.8yrs | US$7.30m | 0.030% € 386.6k | |
| President & COO | less than a year | US$1.88m | 0.018% € 230.2k | |
| Executive VP | 3.3yrs | US$1.50m | 0.0090% € 117.4k | |
| Executive VP | less than a year | US$1.53m | no data | |
| Executive VP & COO | 1.8yrs | no data | no data | |
| Senior VP | no data | no data | no data | |
| Associate Director of Investor & Public Relations | 6.6yrs | no data | no data | |
| Executive VP & Chief Human Resources Officer | 1.3yrs | no data | no data | |
| Executive VP and Chief Corporate Affairs & Advocacy Officer | 2.8yrs | no data | no data | |
| Senior VP & Chief Medical Officer | no data | no data | no data | |
| Executive VP & Chief Strategy Officer | 1.8yrs | no data | 0.0089% € 115.7k | |
| EVP and Head of Research & Development | no data | no data | no data |
1.8yrs
Average Tenure
59.5yo
Average Age
Experienced Management: NVAX's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 1.8yrs | US$7.30m | 0.030% € 386.6k | |
| Independent Director | 4.4yrs | US$187.53k | 0.032% € 410.5k | |
| Independent Director | 14.8yrs | US$189.53k | 0.027% € 357.3k | |
| Independent Director | 3.9yrs | US$185.02k | 0.0065% € 85.2k | |
| Independent Director | 4.1yrs | US$175.28k | 0.0065% € 85.2k | |
| Independent Director | 6yrs | US$174.55k | 0.012% € 153.9k | |
| Independent Director | 2.1yrs | US$191.78k | 0.0065% € 85.2k | |
| Independent Chairman of the Board | 14.6yrs | US$222.53k | 0.039% € 502.4k |
4.3yrs
Average Tenure
62yo
Average Age
Experienced Board: NVAX's board of directors are considered experienced (4.3 years average tenure).